Last reviewed · How we verify
Coronavirus vaccine
The Coronavirus vaccine developed by Beijing 302 Hospital is currently marketed, positioning it as an active player in the global vaccination landscape. A key strength of this vaccine is its key composition patent, which is set to expire in 2028, providing a period of exclusive market protection. The primary risk lies in the competitive environment, where multiple vaccines from other companies are also marketed, potentially impacting market share and revenue.
At a glance
| Generic name | Coronavirus vaccine |
|---|---|
| Sponsor | Beijing 302 Hospital |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations (PHASE4)
- A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes (PHASE1)
- Assessing Safety of Coronavirus Infection (COVID-19) Messenger RNA (mRNA) Vaccine Administration in the Setting of a Previous Adverse Reaction (PHASE4)
- Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals (PHASE2, PHASE3)
- Evaluation of Full Versus Fractional Dose of COVID-19 Vaccine Given as a Booster for the Prevention of COVID-19 in Adults in Mongolia. (PHASE3)
- Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b2) in Chinese Healthy Population (PHASE2)
- An Open Comparative Study of the Effectiveness and Incomparable Study of the Immunogenicity and Safety of the Vaccine (CoviVac) for Adults Aged 60 Years and Older (PHASE2)
- Use and Effectiveness of COVID-19 Vaccines Using State Vaccine Registries and Insurance Claims Data
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Coronavirus vaccine CI brief — competitive landscape report
- Coronavirus vaccine updates RSS · CI watch RSS
- Beijing 302 Hospital portfolio CI